{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-083523","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.937204+00:00","generated_at":"2026-05-23T11:53:56.745941+00:00","sec_items":["1.01","2.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement","bullets":["Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.","Agreement with activist investors Bradley Radoff and Michael Torok: slate withdrawn, standstill and voting commitments through mid-2026.","Franklin Berger will retire from board after his Class I term expires at 2027 annual meeting.","Board authorized up to $25M share repurchase program; strategic alternatives review with Evercore ongoing.","Preliminary cash, cash equivalents and marketable securities as of March 31, 2025: $425.4 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-083523","json":"https://secwatch.observer/filing/0001193125-25-083523.json","markdown":"https://secwatch.observer/filing/0001193125-25-083523.md","text":"https://secwatch.observer/filing/0001193125-25-083523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/d915073d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T11:53:56.745941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56a2893ba9","claim":"Howard H. Berman was appointed as Class III director at Atea Pharmaceuticals, Inc..","evidence_excerpt":"On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"5ce49c7e3b","claim":"Franklin Berger departed as Class I director at Atea Pharmaceuticals, Inc..","evidence_excerpt":"In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525083523/0001193125-25-083523-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}